Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery

Atherosclerosis

Volumn 132, Issue 2, 1997, Pages 215-219

  Delanghe, Joris ^a   Cambier, Bernard ^b   Langlois, Michel ^a   De Buyzere, Marc ^a   Neels, Hugo ^b   De Bacquer, Dirk ^c   Van Cauwelaert, Philippe ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

Acute myocardial infarction; Atherosclerosis; Coronary artery bypass grafting; Haptoglobin; Polymorphism

Indexed keywords

HAPTOGLOBIN;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ALLELES; CORONARY ARTERY BYPASS; CORONARY DISEASE; GENE FREQUENCY; HAPTOGLOBINS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 0030859262     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00089-0     Document Type: Article

References (32)

1. Bowman BH, editor. Haptoglobin. In: Hepatic Plasma Proteins. San Diego: Academic Press, 1993:159-67.
2. Smithies O. Zone electrophoresis in starch gels: grouped variations in the serum proteins of normal human adults. Biochem J 1955;61:629-41.
3. Lange V. Der Haptoglobin Polymorphismus - nicht nur eine genetische Markierungshilfe. Anthrop Anz 1992;50:281-302.
4. Langlois M, Delanghe J. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;46:1589-600.
5. Weinberger M, Miller J, Fineberg N, Luft F, Grim C, Christian J. Association of haptoglobin with sodium sensitivity and resistance of blood pressure. Hypertension 1987;10:443-6.
6. Kojima S, Inenaga T, Matsuoka H, et al. The association between salt-sensitivity of blood pressure and some polymorphic factors. J Hypertens 1994;12:797-801.
7. John A, Henke J, Morich FJ. Identification of a so-far not characterized human serum protein associated with essential hypertension. Electrophoresis 1985;6:292-5.
8. Delanghe J, Duprez D, De Buyzere M, et al. Haptoglobin phenotypes and complications in established essential arterial hypertension. J Hypertens 1993;11:861-7.
9. Delanghe J, Duprez D, De Buyzere M, et al. Refractory hypertension is associated with the haptoglobin 2-2 phenotype. J Cardiovasc Risk 1995;2:131-6.
10. Buckton K, Lai L, Gibson J. A search for association between gene markers and serum cholesterol, triglycerides, urate and blood pressure. Ann Hum Biol 1981;8:39-48.
11. Fröhlander N. Haptoglobin groups and serum cholesterol levels. Hum Hered 1987;37:323-5.
12. Borresen A, Leren T, Berg K, Solaas M. Effect of haptoglobin subtypes on serum lipid levels. Hum Hered 1987;37:150-6.
13. Hanasaki K, Powell L, Varki A. Binding of human plasma sialoglycoproteins by the B cell specific lectin CD22. Selective recognition of immunoglobulin M and haptoglobin. J Biol Chem 1995;270:7543-50.
14. El Ghmati SM, Van Hoeyveld EM, Van Strijp JAG, Ceuppens JL, Stevens EAM. Identification of haptoglobin as an alternative ligand for CD11b/CD18. J Immunol 1996;156:2542-52.
15. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;366:801-9.
16. Chapelle JP, Albert A, Smeets J, Heusgem C, Kulbertus H. Effect of the haptoglobin phenotype on the size of a myocardial infarct. New Engl J Med 1982;307:457-63.
17. Castelli WP. Lipids, risk factors and ischaemic heart disease. Atherosclerosis 1996;124(Suppl):S1-9.
18. Juhan-Vague I. Haemostatic parameters and vascular risk. Atherosclerosis 1996;124(Suppl):S49-55.
19. Frohlich ED. Uric acid. A risk factor for coronary heart disease. JAMA 1993;270:378-9.
20. Allain C, Poon L, Chan C. Enzymatic determination of total cholesterol. Clin Chem 1974;20:470-5.
21. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476-82.
22. Lopes-Virella M, Stone P, Ellis S, Colwell J. Cholesterol determination in high-density lipoproteins separated by three different methods. Clin Chem 1977;23:882-4.
23. Friedewald W, Levy R, Frederickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-509.
24. Town M, Gehm S, Hammer B, Ziegenhorn J. A sensitive method for the enzymatic determination of uric acid. J Clin Chem Clin Biochem 1985;23:591.
25. Frings C, Faulkner W, editors. Cyanide and thiocyanate by microdiffusion and spectrophotometry. In: Selected Methods of Clinical Chemistry. Washington: AACC Press, 1986;11:57-62
26. Duplàa C, Couffinhal T, Labat L, et al. Monocyte/macrophage recruitment and expression of endothelial adhesion proteins in human atherosclerotic lesions. Atherosclerosis 1996;121:253-66.
27. Gutteridge JMC. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995;41:1819-28.
28. Jialal I, Devaraj S. Low-density lipoprotein oxidation, antioxidants and atherosclerosis: a clinical biochemistry perspective. Clin Chem 1996;42:498-506.
29. Liu XS, Zhou M, Chen Y, Wen WY, Sun MJ. Lipoperoxidative injury to macrophages by oxidatively modified low density lipoprotein may play an important role in foam cell formation. Atherosclerosis 1996;121:55-61.
30. Jacob HS. Newly recognized causes of atherosclerosis: the role of microorganisms and of vascular iron overload. J Lab Clin Med 1994;123:808-16.
31. Yuan XM, Wei L, Olsson AG, Brunk UT. Iron in human atheroma and LDL oxidation by macrophages following erythrophagocytosis. Atherosclerosis 1996;124:61-73.
32. Gutteridge JMC. The antioxidant activity of haptoglobin towards haemoglobin-stimulated lipid peroxidation. Biochim Biophys Acta 1987;917:219-23.